Modeling familial amyloidotic polyneuropathy (transthyretin V30M) in drosophila melanogaster

Neurodegenerative Diseases

Volumn 6, Issue 3, 2009, Pages 127-138

  Berg, Ina ^a   Thor, Stefan ^a   Hammarström, Per ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Amyloid disease; Drosophilamelanogaster; Familial amyloidotic polyneuropathy; Transthyretin

Indexed keywords

CONGO RED; MUTANT PROTEIN; PREALBUMIN;

AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VACUOLE; CLIMBING; CONTROLLED STUDY; DISEASE ASSOCIATION; DROSOPHILA MELANOGASTER; EYE; FAMILIAL AMYLOID POLYNEUROPATHY; LIFESPAN; MORPHOLOGICAL TRAIT; NERVOUS SYSTEM; NEUROLOGIC DISEASE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE INJURY; TRANSGENIC ANIMAL; WILD TYPE;

AMINO ACID SEQUENCE; AMYLOID NEUROPATHIES, FAMILIAL; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BASE SEQUENCE; BLOTTING, WESTERN; BRAIN; DISEASE MODELS, ANIMAL; DROSOPHILA MELANOGASTER; EYE; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSCOPY, ELECTRON, SCANNING; MOLECULAR SEQUENCE DATA; MOTOR ACTIVITY; MUTATION; PREALBUMIN;

EID: 64549084878     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000213761     Document Type: Article

References (31)

1. Kelly JW, Colon W, Lai Z, Lashuel HA, Mc-Culloch J, McCutchen SL, Miroy GJ, Peterson SA: Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid. Adv Protein Chem 1997; 50: 161-181.
2. Lai Z, Colon W, Kelly JW: The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can selfassemble into amyloid. Biochemistry 1996; 35: 6470-6482.
3. Hammarstrom P, Schneider F, Kelly JW: Transsuppression of misfolding in an amyloid disease. Science 2001; 293: 2459-2462.
4. Hammarstrom P, Jiang X, Hurshman AR, Powers ET, Kelly JW: Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc Natl Acad Sci USA 2002; 99 (Suppl 4):16427-16432.
5. Bilen J, Bonini NM: Drosophila as a model for human neurodegenerative disease. Annu Rev Genet 2005; 39: 153-171.
6. Jackson GR, Salecker I, Dong X, Yao X, Arnheim N, Faber PW, MacDonald ME, Zipursky SL: Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 1998; 21: 633-642.
7. Crowther DC, Page R, Chandraratna D, Lomas DA: A Drosophila model of Alzheimer's disease. Methods Enzymol 2006; 412: 234-255.
8. Feany MB, Bender WW: A Drosophila model of Parkinson's disease. Nature 2000; 404: 394-398.
9. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, Feany MB: Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 2001; 293: 711-714.
10. Gavin BA, Dolph MJ, Deleault NR, Geoghegan JC, Khurana V, Feany MB, Dolph PJ, Supattapone S: Accelerated accumulation of misfolded prion protein and spongiform degeneration in a Drosophila model of Gerstmann-Sträussler- Scheinker syndrome. J Neuro sci 2006; 26: 12408-12414.
11. Pokrzywa M, Dacklin I, Hultmark D, Lundgren E: Misfolded transthyretin causes behavioral changes in a drosophila model for transthyretin-associated amyloidosis. Eur J Neurosci 2007; 26: 913-924.
12. Brand AH, Perrimon N: Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 1993; 118: 401-415.
13. Crowther DC, Kinghorn KJ, Miranda E, Page R, Curry JA, Duthie FA, Gubb DC, Lomas DA: Intraneuronal abeta, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. Neuroscience 2005; 132: 123-135.4
14. Spradling AC, Rubin GM: Transposition of cloned P elements into Drosophila germ line chromosomes. Science 1982; 218: 341-347.
15. Lin DM, Goodman CS: Ectopic and increased expression of Fasciclin II alters motoneuron growth cone guidance. Neuron 1994; 13: 507-523.
16. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
17. Hay BA, Wolff T, Rubin GM: Expression of baculovirus P35 prevents cell death in Drosophila. Development 1994; 120: 2121-2129.
18. Huang JT, Leweke FM, Oxley D, Wang L, Harris N, Koethe D, Gerth CW, Nolden BM, Gross S, Schreiber D, Reed B, Bahn S: Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med 2006; 3: e428.
19. Schreiber G: The evolutionary and integrative roles of transthyretin in thyroid hormone homeostasis. J Endocrinol 2002; 175: 61-73.
20. Takaoka Y, Ohta M, Miyakawa K, Nakamura O, Suzuki M, Takahashi K, Yamamura K, Sakaki Y: Cysteine 10 is a key residue in amyloidogenesis of human transthyretin Val-30met. Am J Pathol 2004; 164: 337-345.
21. Teng MH, Yin JY, Vidal R, Ghiso J, Kumar A, Rabenou R, Shah A, Jacobson DR, Tagoe C, Gallo G, Buxbaum J: Amyloid and nonfibrillar deposits in mice transgenic for wild-type human transthyretin: a possible model for senile systemic amyloidosis. Lab Invest 2001; 81: 385-396.
22. Hammarstrom P, Wiseman RL, Powers ET, Kelly JW: Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003; 299: 713-716.
23. Sekijima Y, Wiseman RL, Matteson J, Hammarstrom P, Miller SR, Sawkar AR, Balch WE, Kelly JW: The biological and chemical basis for tissue-selective amyloid disease. Cell 2005; 121: 73-85.
24. Reixach N, Foss TR, Santelli E, Pascual J, Kelly JW, Buxbaum JN: Human-murine transthyretin heterotetramers are kinetically stable and non-amyloidogenic. J Biol Chem 2008; 283: 2098-2107.
25. Tagoe CE, Reixach N, Friske L, Mustra D, French D, Gallo G, Buxbaum JN: In vivo stabilization of mutant human transthyretin in transgenic mice. Amyloid 2007; 14: 227-236.
26. Gregory SL, Shandala T, O'Keefe L, Jones L, Murray MJ, Saint R: A Drosophila overexpression screen for modifiers of rho signalling in cytokinesis. Fly 2007; 1: 13-22.
27. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM: Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002; 295: 865-868.
28. Westermark P, Sletten K, Johansson B, Cornwell GG 3rd: Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 1990; 87: 2843-2845.
29. Sandgren O, Holmgren G, Lundgren E: Vitreous amyloidosis associated with homozygosity for the transthyretin methionine-30 gene. Arch Ophthalmol 1990; 108: 1584-1586.
30. Munar-Ques M, Salva-Ladaria L, Mulet-Perera P, Sole M, Lopez-Andreu FR, Saraiva MJ: Vitreous amyloidosis after liver transplantation in patients with familial amyloid polyneuropathy: ocular synthesis of mutant transthyretin. Amyloid 2000; 7: 266-269.
31. Kawaji T, Ando Y, Ando E, Nakamura M, Hirata A, Tanihara H: A case of vitreous amyloidosis without systemic symptoms in familial amyloidotic polyneuropathy. Amyloid 2004; 11: 257-259.